Londoner first to participate in experimental lung cancer vaccine trial

Janusz Racz, 67-year-old Londonermade history by becoming first participant in the study a new experimental vaccine against lung cancer. You will be one of 130 patients with non-small cell lung cancer (NSCLC) at various stages, from early stages before surgery or radiation therapy to advanced disease, at 34 study sites in seven countries.

Raz, a patient at University College London Hospital (UCLH), was lung cancer was diagnosed in Mayand began chemotherapy and radiotherapy a few days later. Lung cancer caused 1.8 million deaths in 2020. Almost a quarter of a million people are from the European Union, accounting for almost one in five cancer deaths in the region.

Six Spanish hospital centres will take part in a study of an experimental vaccine against lung cancer.

This revolutionary global test lung cancer vaccines, in addition United Kingdomin four other European countries, Germany, Spain, Poland And Hungaryand also in USA And TürkiyeIn our country, the participating centres will be the La Fe University and Polytechnic Hospital (Valencia), the Virgen de la Macarena Hospital (Seville), the Jimenez Diaz Foundation (Madrid), the University Hospital Complex of Santiago de Compostela, as well as Vall d’Hebron and Geman Trias i Pujol in Barcelona.

The team’s researchers hope that this vaccine will provide one or morethe opportunity to continue improving results our patients with NSCLC, whether they are in early or advanced stages.

the objectives of this study The goal is to determine whether the immunotherapy, known as BNT116, is safe and well-tolerated, whether it is effective on its own in fighting tumors, and whether it can work with traditional chemotherapy or immunotherapy treatments to more effectively target tumors.

MESSENGER RNA VACCINE

A vaccine called BNT116 and developed by BioNTech, uses messenger RNA technology (mRNA), similar to that used in some COVID-19 vaccines, that helps the immune system recognize and attack cancer cells. The vaccine is designed to specifically boost the immune response against targets expressed predominantly by cancer cells. reducing the risk of toxicity to healthy cellsadvantage over the current effects of chemotherapy.

Siou Ming Lee, consultant medical oncologist at UCLH, who is leading the national study, said: “Lung cancer remains the leading cause of cancer deaths worldwide. We are entering this new and exciting era. Clinical trials of mRNA-based immunotherapy to study the treatment of lung cancer.”

“Strong side approach We accept that treatment highly targeted to cancer cells” said Dr. Sarah Benafif, who led the study. “So we hope that over time we will be able to demonstrate that the treatment is effective against lung cancer without affecting other tissues,” he concluded.